View Item 

Show simple item record

Cystic Fibrosis Foundation otolaryngology care multidisciplinary consensus recommendations
dc.contributor.authorKimple, Adam J.
dc.contributor.authorSenior, Brent A.
dc.contributor.authorNaureckas, Edward T.
dc.contributor.authorGudis, David A.
dc.contributor.authorMeyer, Ted
dc.contributor.authorHempstead, Sarah E.
dc.contributor.authorResnick, Helaine E.
dc.contributor.authorAlbon, Dana
dc.contributor.authorBarfield, Wayne
dc.contributor.authorBenoit, Margo McKenna
dc.contributor.authorBeswick, Daniel M.
dc.contributor.authorCallard, Eliza
dc.contributor.authorCofer, Shelagh
dc.contributor.authorDowner, Veronica
dc.contributor.authorElson, E. Claire
dc.contributor.authorGarinis, Angela
dc.contributor.authorHalderman, Ashleigh
dc.contributor.authorHamburger, Lisa
dc.contributor.authorHelmick, Meagan
dc.contributor.authorMcCown, Michael
dc.contributor.authorMcKinzie, Cameron J.
dc.contributor.authorPhan, Hanna
dc.contributor.authorRodriguez, Kenneth
dc.contributor.authorRubenstein, Ronald C.
dc.contributor.authorSeverin, Ashley
dc.contributor.authorShah, Gopi
dc.contributor.authorShenoy, Ambika
dc.contributor.authorSprouse, Brittney
dc.contributor.authorVirgin, Frank
dc.contributor.authorWoodworth, Bradford A.
dc.contributor.authorLee, Stella E.
dc.date.accessioned2022-09-26T16:01:34Z
dc.date.available2023-10-26 12:01:33en
dc.date.available2022-09-26T16:01:34Z
dc.date.issued2022-09
dc.identifier.citationKimple, Adam J.; Senior, Brent A.; Naureckas, Edward T.; Gudis, David A.; Meyer, Ted; Hempstead, Sarah E.; Resnick, Helaine E.; Albon, Dana; Barfield, Wayne; Benoit, Margo McKenna; Beswick, Daniel M.; Callard, Eliza; Cofer, Shelagh; Downer, Veronica; Elson, E. Claire; Garinis, Angela; Halderman, Ashleigh; Hamburger, Lisa; Helmick, Meagan; McCown, Michael; McKinzie, Cameron J.; Phan, Hanna; Rodriguez, Kenneth; Rubenstein, Ronald C.; Severin, Ashley; Shah, Gopi; Shenoy, Ambika; Sprouse, Brittney; Virgin, Frank; Woodworth, Bradford A.; Lee, Stella E. (2022). "Cystic Fibrosis Foundation otolaryngology care multidisciplinary consensus recommendations." International Forum of Allergy & Rhinology 12(9): 1089-1103.
dc.identifier.issn2042-6976
dc.identifier.issn2042-6984
dc.identifier.urihttps://hdl.handle.net/2027.42/174767
dc.description.abstractBackgroundCystic fibrosis (CF) is a multisystem disease that often requires otolaryngology care. Individuals with CF commonly have chronic rhinosinusitis but also present with hearing loss and dysphonia. Given these manifestations of CF, otolaryngologists are frequently involved in the care of patients with CF; however, there is limited consensus on optimal management of sinonasal, otologic, and laryngologic symptoms.MethodsThe Cystic Fibrosis Foundation convened a multidisciplinary team of otolaryngologists, pulmonologists, audiologists, pharmacists, a social worker, a nurse coordinator, a respiratory therapist, two adults with CF, and a caregiver of a child with CF to develop consensus recommendations. Workgroups developed draft recommendation statements based on a systematic literature review, and a ≥80% consensus was required for acceptance of each recommendation statement.ResultsThe committee voted on 25 statements. Eleven statements were adopted recommending a treatment or intervention, while five statements were formulated recommending against a specific treatment or intervention. The committee recommended eight statements as an option for select patients in certain circumstances, and one statement did not reach consensus.ConclusionThese multidisciplinary consensus recommendations will help providers navigate decisions related to otolaryngology consultation, medical and surgical management of CF‐CRS, hearing, and voice in individuals with CF. A collaborative and multidisciplinary approach is advocated to best care for our patients with CF. Future clinical research is needed utilizing standardized, validated outcomes with comprehensive reporting of patient outcome, effects of modulator therapies, and genetic characteristics to help continue to advance care, decrease morbidity, and improve the quality of life for individuals with CF.
dc.publisherWiley Periodicals, Inc.
dc.subject.otherchronic rhinosinusitis
dc.subject.othervoice and allergy
dc.subject.othersinus
dc.subject.otherFESS
dc.subject.otherevidence‐based medicine
dc.subject.otherdysphonia
dc.subject.othercystic fibrosis
dc.titleCystic Fibrosis Foundation otolaryngology care multidisciplinary consensus recommendations
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelAllergy and Clinical Immunology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/174767/1/alr22974_am.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/174767/2/alr22974.pdf
dc.identifier.doi10.1002/alr.22974
dc.identifier.sourceInternational Forum of Allergy & Rhinology
dc.identifier.citedreferencePiccirillo JF, Payne SC, Rosenfeld RM, et al. Clinical consensus statement: balloon dilation of the sinuses. Otolaryngol Head Neck Surg. 2018; 158 ( 2 ): 203 – 214.
dc.identifier.citedreferenceArnaoutakis D, Collins WO. Correlation of mucociliary clearance and symptomatology before and after adenoidectomy in children. Int J Pediatr Otorhinolaryngol. 2011; 75 ( 10 ): 1318 – 1321.
dc.identifier.citedreferenceRamadan HH, Makary CA. Can computed tomography score predict outcome of adenoidectomy for chronic rhinosinusitis in children. Am J Rhinol Allergy. 2014; 28 ( 1 ): e80 – 2.
dc.identifier.citedreferenceBerkhout MC, Klerx‐Melis F, Fokkens WJ, Nuijsink M, van Aalderen WM, Heijerman HG. CT‐abnormalities, bacteriology and symptoms of sinonasal disease in children with cystic fibrosis. J Cyst Fibros. 2016; 15 ( 6 ): 816 – 824.
dc.identifier.citedreferenceGergin O, Kawai K, MacDougall RD, et al. Sinus computed tomography imaging in pediatric cystic fibrosis: added value? Otolaryngol Head Neck Surg. 2016; 155 ( 1 ): 160 – 165.
dc.identifier.citedreferenceCalixto NE, Gregg‐Jaymes T, Liang J, Jiang N. Sinus procedures in the Medicare population from 2000 to 2014: a recent balloon sinuplasty explosion. Laryngoscope. 2017; 127 ( 9 ): 1976 – 1982.
dc.identifier.citedreferenceRamadan HH. Safety and feasibility of balloon sinuplasty for treatment of chronic rhinosinusitis in children. Ann Otol Rhinol Laryngol. 2009; 118 ( 3 ): 161 – 165.
dc.identifier.citedreferenceJia L, Cao C, Jing B, et al. 3‐Year follow‐up after balloon sinuplasty in children with chronic rhinosinusitis. Int J Pediatr Otorhinolaryngol. 2020; 136: 110084.
dc.identifier.citedreferenceGould J, Alexander I, Tomkin E, Brodner D. In‐office, multisinus balloon dilation: 1‐year outcomes from a prospective, multicenter, open label trial. Am J Rhinol Allergy. 2014; 28 ( 2 ): 156 – 163.
dc.identifier.citedreferenceBolger WE, Brown CL, Church CA, et al. Safety and outcomes of balloon catheter sinusotomy: a multicenter 24‐week analysis in 115 patients. Otolaryngol Head Neck Surg. 2007; 137 ( 1 ): 10 – 20.
dc.identifier.citedreferenceBrihaye P, Clement PA, Dab I, Desprechin B. Pathological changes of the lateral nasal wall in patients with cystic fibrosis (mucoviscidosis). Int J Pediatr Otorhinolaryngol. 1994; 28 ( 2–3 ): 141 – 147.
dc.identifier.citedreferenceCepero R, Smith RJ, Catlin FI, Bressler KL, Furuta GT, Shandera KC. Cystic fibrosis–an otolaryngologic perspective. Otolaryngol Head Neck Surg. 1987; 97 ( 4 ): 356 – 360.
dc.identifier.citedreferenceGentile VG, Isaacson G. Patterns of sinusitis in cystic fibrosis. Laryngoscope. 1996; 106 ( 8 ): 1005 – 1009.
dc.identifier.citedreferenceRosbe KW, Jones DT, Rahbar R, Lahiri T, Auerbach AD. Endoscopic sinus surgery in cystic fibrosis: do patients benefit from surgery? Int J Pediatr Otorhinolaryngol. 2001; 61 ( 2 ): 113 – 119.
dc.identifier.citedreferenceGysin C, Alothman GA, Papsin BC. Sinonasal disease in cystic fibrosis: clinical characteristics, diagnosis, and management. Pediatr Pulmonol. 2000; 30 ( 6 ): 481 – 489.
dc.identifier.citedreferenceDiMango E, Spielman DB, Overdevest J, et al. Effect of highly effective modulator therapy on quality of life in adults with cystic fibrosis. Int Forum Allergy Rhinol. 2021; 11 ( 1 ): 75 – 78.
dc.identifier.citedreferenceBeer H, Southern KW, Swift AC. Topical nasal steroids for treating nasal polyposis in people with cystic fibrosis. Cochrane Database Syst Rev. 2015 ( 6 ): CD008253.
dc.identifier.citedreferenceZemke AC, Nouraie SM, Moore J, et al. Clinical predictors of cystic fibrosis chronic rhinosinusitis severity. Int Forum Allergy Rhinol. 2019; 9 ( 7 ): 759 – 765.
dc.identifier.citedreferenceChandy Z, Ference E, Lee JT. Clinical guidelines on chronic rhinosinusitis in children. Curr Allergy Asthma Rep. 2019; 19 ( 2 ): 14.
dc.identifier.citedreferenceRosenfeld RM, Piccirillo JF, Chandrasekhar SS, et al. Clinical practice guideline (update): adult sinusitis. Otolaryngol Head Neck Surg. 2015; 152 ( 2 Suppl): S1 – S39.
dc.identifier.citedreferenceVirgin FW, Rowe SM, Wade MB, et al. Extensive surgical and comprehensive postoperative medical management for cystic fibrosis chronic rhinosinusitis. Am J Rhinol Allergy. 2012; 26 ( 1 ): 70 – 75.
dc.identifier.citedreferenceWoodworth BA, Parker RO, Schlosser RJ. Modified endoscopic medial maxillectomy for chronic maxillary sinusitis. Am J Rhinol. 2006; 20 ( 3 ): 317 – 319.
dc.identifier.citedreferenceCho DY, Hwang PH. Results of endoscopic maxillary mega‐antrostomy in recalcitrant maxillary sinusitis. Am J Rhinol. 2008; 22 ( 6 ): 658 – 662.
dc.identifier.citedreferenceIlling EA, Cho DY, Riley KO, Woodworth BA. Draf III mucosal graft technique: long‐term results. Int Forum Allergy Rhinol. 2016; 6 ( 5 ): 514 – 517.
dc.identifier.citedreferenceIlling EA, Woodworth BA. Management of the upper airway in cystic fibrosis. Curr Opin Pulm Med. 2014; 20 ( 6 ): 623 – 631.
dc.identifier.citedreferenceChaaban MR, Kejner A, Rowe SM, Woodworth BA. Cystic fibrosis chronic rhinosinusitis: a comprehensive review. Am J Rhinol Allergy. 2013; 27 ( 5 ): 387 – 395.
dc.identifier.citedreferenceShatz A. Management of recurrent sinus disease in children with cystic fibrosis: a combined approach. Otolaryngol Head Neck Surg. 2006; 135 ( 2 ): 248 – 252.
dc.identifier.citedreferenceUmetsu DT, Moss RB, King VV, Lewiston NJ. Sinus disease in patients with severe cystic fibrosis: relation to pulmonary exacerbation. Lancet. 1990; 335 ( 8697 ): 1077 – 1078.
dc.identifier.citedreferenceKempainen RR, Sajan JA, Pylkas AM, Dunitz JM, Rimell FL, Milla CE. Effect of endoscopic sinus surgery on pulmonary status of adults with cystic fibrosis. Otolaryngol Head Neck Surg. 2012; 147 ( 3 ): 557 – 562.
dc.identifier.citedreferenceMainz JG, Schadlich K, Schien C, et al. Sinonasal inhalation of tobramycin vibrating aerosol in cystic fibrosis patients with upper airway Pseudomonas aeruginosa colonization: results of a randomized, double‐blind, placebo‐controlled pilot study. Drug Des Devel Ther. 2014; 8: 209 – 217.
dc.identifier.citedreferenceDi Cicco M, Alicandro G, Claut L, et al. Efficacy and tolerability of a new nasal spray formulation containing hyaluronate and tobramycin in cystic fibrosis patients with bacterial rhinosinusitis. J Cyst Fibros. 2014; 13 ( 4 ): 455 – 460.
dc.identifier.citedreferenceBerkhout MC, van Velzen AJ, Touw DJ, de Kok BM, Fokkens WJ, Heijerman HG. Systemic absorption of nasally administered tobramycin and colistin in patients with cystic fibrosis. J Antimicrob Chemother. 2014; 69 ( 11 ): 3112 – 3115.
dc.identifier.citedreferenceMainz JG, Schumacher U, Schadlich K, et al. Sino nasal inhalation of isotonic versus hypertonic saline (6.0%) in CF patients with chronic rhinosinusitis ‐ Results of a multicenter, prospective, randomized, double‐blind, controlled trial. J Cyst Fibros. 2016; 15 ( 6 ): e57 – e66.
dc.identifier.citedreferenceCimmino M, Nardone M, Cavaliere M, et al. Dornase alfa as postoperative therapy in cystic fibrosis sinonasal disease. Arch Otolaryngol Head Neck Surg. 2005; 131 ( 12 ): 1097 – 1101.
dc.identifier.citedreferenceShah GB, De Keyzer L, Russell JA, Halderman A. Treatment of chronic rhinosinusitis with dornase alfa in patients with cystic fibrosis: a systematic review. Int Forum Allergy Rhinol. 2018; 8 ( 6 ): 729 – 736.
dc.identifier.citedreferenceHadfield PJ, Rowe‐Jones JM, Mackay IS. A prospective treatment trial of nasal polyps in adults with cystic fibrosis. Rhinology. 2000; 38 ( 2 ): 63 – 65.
dc.identifier.citedreferenceDe Wachter E, Vanbesien J, De Schutter I, Malfroot A, De Schepper J. Rapidly developing Cushing syndrome in a 4‐year‐old patient during combined treatment with itraconazole and inhaled budesonide. Eur J Pediatr. 2003; 162 ( 7–8 ): 488 – 489.
dc.identifier.citedreferenceDe Wachter E, Malfroot A, De Schutter I, Vanbesien J, De Schepper J. Inhaled budesonide induced Cushing’s syndrome in cystic fibrosis patients, due to drug inhibition of cytochrome P450. J Cyst Fibros. 2003; 2 ( 2 ): 72 – 75.
dc.identifier.citedreferenceLee SE, Farzal Z, Daniels MLA, et al. Cystic fibrosis transmembrane conductance regulator modulator therapy: a review for the otolaryngologist. Am J Rhinol Allergy. 2020; 34 ( 4 ): 573 – 580.
dc.identifier.citedreferenceDouglas JE, Civantos AM, Locke TB, et al. Impact of novel CFTR modulator on sinonasal quality of life in adult patients with cystic fibrosis. Int Forum Allergy Rhinol. 2021; 11 ( 2 ): 201 – 203.
dc.identifier.citedreferenceBeswick DM, Humphries SM, Balkissoon CD, et al. Impact of CFTR therapy on chronic rhinosinusitis and health status: deep learning CT analysis and patient reported outcomes. Ann Am Thorac Soc. 2021; 19 ( 1 ).
dc.identifier.citedreferenceAl‐Malky G, Dawson SJ, Sirimanna T, Bagkeris E, Suri R. High‐frequency audiometry reveals high prevalence of aminoglycoside ototoxicity in children with cystic fibrosis. J Cyst Fibros. 2015; 14 ( 2 ): 248 – 254.
dc.identifier.citedreferenceHandelsman JA, Nasr SZ, Pitts C, King WM. Prevalence of hearing and vestibular loss in cystic fibrosis patients exposed to aminoglycosides. Pediatr Pulmonol. 2017; 52 ( 9 ): 1157 – 1162.
dc.identifier.citedreferenceOlivier KN, Shaw PA, Glaser TS, et al. Inhaled amikacin for treatment of refractory pulmonary nontuberculous mycobacterial disease. Ann Am Thorac Soc. 2014; 11 ( 1 ): 30 – 35.
dc.identifier.citedreferenceOlivier KN, Griffith DE, Eagle G, et al. Randomized trial of liposomal amikacin for inhalation in nontuberculous mycobacterial lung disease. Am J Respir Crit Care Med. 2017; 195 ( 6 ): 814 – 823.
dc.identifier.citedreferenceMarissen J, Fortmann I, Humberg A, et al. Vancomycin‐induced ototoxicity in very‐low‐birthweight infants. J Antimicrob Chemother. 2020; 75 ( 8 ): 2291 – 2298.
dc.identifier.citedreferenceHumphrey C, Veve MP, Walker B, Shorman MA. Long‐term vancomycin use had low risk of ototoxicity. PLoS One. 2019; 14 ( 11 ): e0224561.
dc.identifier.citedreferenceBizjak ED, Haug MT 3rd, Schilz RJ, Sarodia BD, Dresing JM. Intravenous azithromycin‐induced ototoxicity. Pharmacotherapy. 1999; 19 ( 2 ): 245 – 248.
dc.identifier.citedreferenceSwanson DJ, Sung RJ, Fine MJ, Orloff JJ, Chu SY, Yu VL. Erythromycin ototoxicity: prospective assessment with serum concentrations and audiograms in a study of patients with pneumonia. Am J Med. 1992; 92 ( 1 ): 61 – 68.
dc.identifier.citedreferenceHeffernan CB, McKeon MG, Molony S, et al. Does clarithromycin cause hearing loss? A 12‐year review of clarithromycin therapy for nontuberculous mycobacterial lymphadenitis in children. Ann Otol Rhinol Laryngol. 2018; 127 ( 10 ): 687 – 693.
dc.identifier.citedreferenceMick P, Westerberg BD. Sensorineural hearing loss as a probable serious adverse drug reaction associated with low‐dose oral azithromycin. J Otolaryngol. 2007; 36 ( 5 ): 257 – 263.
dc.identifier.citedreferenceDay RO, Graham GG, Bieri D, et al. Concentration‐response relationships for salicylate‐induced ototoxicity in normal volunteers. Br J Clin Pharmacol. 1989; 28 ( 6 ): 695 – 702.
dc.identifier.citedreferenceMcKinnon BJ, Lassen LF. Naproxen‐associated sudden sensorineural hearing loss. Mil Med. 1998; 163 ( 11 ): 792 – 793.
dc.identifier.citedreferenceTrust CF. Standards for the Clinical Care of Children and Adults with cystic fibrosis in the UK. Trust CF; 2011.
dc.identifier.citedreferenceCrawford I, Maloney PC, Zeitlin PL, et al. Immunocytochemical localization of the cystic fibrosis gene product CFTR. Proc Natl Acad Sci USA. 1991; 88 ( 20 ): 9262 – 9266.
dc.identifier.citedreferenceDenning GM, Ostedgaard LS, Cheng SH, Smith AE, Welsh MJ. Localization of cystic fibrosis transmembrane conductance regulator in chloride secretory epithelia. J Clin Invest. 1992; 89 ( 1 ): 339 – 349.
dc.identifier.citedreferenceTrezise AE, Buchwald M. In vivo cell‐specific expression of the cystic fibrosis transmembrane conductance regulator. Nature. 1991; 353 ( 6343 ): 434 – 437.
dc.identifier.citedreferenceTipirneni KE, Woodworth BA. Medical and surgical advancements in the management of cystic fibrosis chronic rhinosinusitis. Curr Otorhinolaryngol Rep. 2017; 5 ( 1 ): 24 – 34.
dc.identifier.citedreferenceFokkens WJ, Lund VJ, Hopkins C, et al. European Position Paper on rhinosinusitis and nasal polyps 2020. Rhinology. 2020; 58 (Suppl S29 ): 1 – 464.
dc.identifier.citedreferenceLiang J, Higgins T, Ishman SL, Boss EF, Benke JR, SY Lin. Medical management of chronic rhinosinusitis in cystic fibrosis: a systematic review. Laryngoscope. 2014; 124 ( 6 ): 1308 – 1313.
dc.identifier.citedreferenceOrlandi RR, Kingdom TT, Smith TL, et al. International consensus statement on allergy and rhinology: rhinosinusitis 2021. Int Forum Allergy Rhinol. 2021; 11 ( 3 ): 213 – 739.
dc.identifier.citedreferenceJiang M, Karasawa T, Steyger PS. Aminoglycoside‐induced cochleotoxicity: a review. Front Cell Neurosci. 2017; 11: 308.
dc.identifier.citedreferenceHansen MP, Scott AM, McCullough A, et al. Adverse events in people taking macrolide antibiotics versus placebo for any indication. Cochrane Database Syst Rev. 2019; 1: CD011825.
dc.identifier.citedreferenceIkeda AK, Prince AA, Chen JX, Lieu JEC, Shin JJ. Macrolide‐associated sensorineural hearing loss: a systematic review. Laryngoscope. 2018; 128 ( 1 ): 228 – 236.
dc.identifier.citedreferenceGarinis AC, Cross CP, Srikanth P, et al. The cumulative effects of intravenous antibiotic treatments on hearing in patients with cystic fibrosis. J Cyst Fibros. 2017; 16 ( 3 ): 401 – 409.
dc.identifier.citedreferenceZettner EM, Gleser MA. Progressive hearing loss among patients with cystic fibrosis and parenteral aminoglycoside treatment. Otolaryngol Head Neck Surg. 2018; 159 ( 5 ): 887 – 894.
dc.identifier.citedreferenceElson EC, Meier E, Oermann CM. The implementation of an aminoglycoside induced ototoxicity algorithm for people with cystic fibrosis. J Cyst Fibros. 2021; 20 ( 2 ): 284 – 287.
dc.identifier.citedreferenceLi CM, Zhang X, Hoffman HJ, Cotch MF, Themann CL, Wilson MR. Hearing impairment associated with depression in US adults, National Health and Nutrition Examination Survey 2005–2010. JAMA Otolaryngol Head Neck Surg. 2014; 140 ( 4 ): 293 – 302.
dc.identifier.citedreferenceMick P, Kawachi I, Lin FR. The association between hearing loss and social isolation in older adults. Otolaryngol Head Neck Surg. 2014; 150 ( 3 ): 378 – 384.
dc.identifier.citedreferenceDeal JA, Betz J, Yaffe K, et al. Hearing impairment and incident dementia and cognitive decline in older adults: the Health ABC Study. J Gerontol A Biol Sci Med Sci. 2017; 72 ( 5 ): 703 – 709.
dc.identifier.citedreferenceDawes P, Emsley R, Cruickshanks KJ, et al. Hearing loss and cognition: the role of hearing AIDS, social isolation and depression. PLoS One. 2015; 10 ( 3 ): e0119616.
dc.identifier.citedreferenceSaiman L, Siegel JD, LiPuma JJ, et al. Infection prevention and control guideline for cystic fibrosis: 2013 update. Infect Control Hosp Epidemiol. 2014; 35 Suppl 1: S1 – S67.
dc.identifier.citedreferenceFloto RA, Olivier KN, Saiman L, et al. US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non‐tuberculous mycobacteria in individuals with cystic fibrosis. Thorax. 2016; 71 Suppl 1: i1 – 22.
dc.identifier.citedreferenceSchwarzenberg SJ, Hempstead SE, McDonald CM, et al. Enteral tube feeding for individuals with cystic fibrosis: cystic Fibrosis Foundation evidence‐informed guidelines. J Cyst Fibros. 2016; 15 ( 6 ): 724 – 735.
dc.identifier.citedreferenceChan DK, McNamara S, Park JS, Vajda J, Gibson RL, Parikh SR. Sinonasal quality of life in children with cystic fibrosis. JAMA Otolaryngol Head Neck Surg. 2016; 142 ( 8 ): 743 – 749.
dc.identifier.citedreferenceHabib AR, Quon BS, Buxton JA, et al. The Sino‐Nasal Outcome Test‐22 as a tool to identify chronic rhinosinusitis in adults with cystic fibrosis. Int Forum Allergy Rhinol. 2015; 5 ( 12 ): 1111 – 1117.
dc.identifier.citedreferenceRegistry CFP. 2019 Annual Data Report. Foundation CF, Bethesda, Maryland; 2020.
dc.identifier.citedreferenceCastellani C, Duff AJA, Bell SC, et al. ECFS best practice guidelines: the 2018 revision. J Cyst Fibros. 2018; 17 ( 2 ): 153 – 178.
dc.identifier.citedreferenceSurgical Advisory Panel AAoP, Klein MD, Surgical Advisory Panel AAoP. Referral to pediatric surgical specialists. Pediatrics. 2014; 133 ( 2 ): 350 – 356.
dc.identifier.citedreferenceThamboo A, Santos RC, Naidoo L, Rahmanian R, Chilvers MA, Chadha NK. Use of the SNOT‐22 and UPSIT to appropriately select pediatric patients with cystic fibrosis who should be referred to an otolaryngologist: cross‐sectional study. JAMA Otolaryngol Head Neck Surg. 2014; 140 ( 10 ): 934 – 939.
dc.identifier.citedreferenceLiang J, Higgins TS, Ishman SL, Boss EF, Benke JR, SY Lin. Surgical management of chronic rhinosinusitis in cystic fibrosis: a systematic review. Int Forum Allergy Rhinol. 2013; 3 ( 10 ): 814 – 822.
dc.identifier.citedreferenceMcCormick J, Cho DY, Lampkin B, et al. Ivacaftor improves rhinologic, psychologic, and sleep‐related quality of life in G551D cystic fibrosis patients. Int Forum Allergy Rhinol. 2019; 9 ( 3 ): 292 – 297.
dc.identifier.citedreferenceKay DJ, Rosenfeld RM. Quality of life for children with persistent sinonasal symptoms. Otolaryngol Head Neck Surg. 2003; 128 ( 1 ): 17 – 26.
dc.identifier.citedreferenceXie DX, Wu J, Kelly K, Brown RF, Shannon C, Virgin FW. Evaluating the sinus and Nasal Quality of Life Survey in the pediatric cystic fibrosis patient population. Int J Pediatr Otorhinolaryngol. 2017; 102: 133 – 137.
dc.identifier.citedreferenceHopkins C, Gillett S, Slack R, Lund VJ, Browne JP. Psychometric validity of the 22‐item Sinonasal Outcome Test. Clin Otolaryngol. 2009; 34 ( 5 ): 447 – 454.
dc.identifier.citedreferenceDiMango E, Overdevest J, Keating C, Francis SF, Dansky D, Gudis D. Effect of highly effective modulator treatment on sinonasal symptoms in cystic fibrosis. J Cyst Fibros. 2021; 20 ( 3 ): 460 – 463.
dc.identifier.citedreferenceLuparello P, Lazio MS, Voltolini L, Borchi B, Taccetti G, Maggiore G. Outcomes of endoscopic sinus surgery in adult lung transplant patients with cystic fibrosis. Eur Arch Otorhinolaryngol. 2019; 276 ( 5 ): 1341 – 1347.
dc.identifier.citedreferenceSuccar EF, Turner JH, Chandra RK. Nasal saline irrigation: a clinical update. Int Forum Allergy Rhinol. 2019; 9 ( S1 ): S4 – S8.
dc.identifier.citedreferenceCasale M, Moffa A, Cassano M, et al. Saline nasal irrigations for chronic rhinosinusitis: from everyday practice to evidence‐based medicine. An update. Int J Immunopathol Pharmacol. 2018; 32: 2058738418802676.
dc.identifier.citedreferenceHarvey R, Hannan SA, Badia L, Scadding G. Nasal saline irrigations for the symptoms of chronic rhinosinusitis. Cochrane Database Syst Rev. 2007 ( 3 ): CD006394.
dc.identifier.citedreferencePrevention and Control. Accessed August 17, 2021. Pages https://www.cdc.gov/parasites/naegleria/sinus‐rinsing.html.
dc.identifier.citedreferenceHallstrand TS, Calenoff E, Becker JW, Henderson WR. The role of allergy in manifestations of respiratory disease in adult cystic fibrosis. Ann Allergy Asthma Immunol. 2004; 92 ( 2 ): 228 – 233.
dc.identifier.citedreferenceWang D, Brihaye P, Smitz J, De Waele M, Clement P. Inflammatory cells and mediator concentrations in nasal secretions of patients with cystic fibrosis. Acta Otolaryngol. 1996; 116 ( 3 ): 472 – 476.
dc.identifier.citedreferenceWeber A, Kiefer J, Peters S, Schneider M, Bargon J, May A. Eosinophilic cationic protein as a marker of nasal inflammation in patients with cystic fibrosis. Laryngoscope. 1999; 109 ( 10 ): 1696 – 1702.
dc.identifier.citedreferenceBrozek JL, Bousquet J, Agache I, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines‐2016 revision. J Allergy Clin Immunol. 2017; 140 ( 4 ): 950 – 958.
dc.identifier.citedreferenceBrown T. Diagnosis and management of allergic rhinitis in children. Pediatr Ann. 2019; 48 ( 12 ): e485 – e488.
dc.identifier.citedreferenceLazio MS, Luparello P, Mannelli G, et al. Quality of life and impact of endoscopic sinus surgery in adult patients with cystic fibrosis. Am J Rhinol Allergy. 2019; 33 ( 4 ): 413 – 419.
dc.identifier.citedreferenceSavastano V, Bertin S, Vittori T, Tripodi C, Magliulo G. Evaluation of chronic rhinosinusitis management using the SNOT‐22 in adult cystic fibrosis patients. Eur Rev Med Pharmacol Sci. 2014; 18 ( 14 ): 1985 – 1989.
dc.identifier.citedreferenceKhalid AN, Mace J, Smith TL. Outcomes of sinus surgery in adults with cystic fibrosis. Otolaryngol Head Neck Surg. 2009; 141 ( 3 ): 358 – 363.
dc.identifier.citedreferenceAanaes K, Johansen HK, Skov M, et al. Clinical effects of sinus surgery and adjuvant therapy in cystic fibrosis patients – can chronic lung infections be postponed? Rhinology. 2013; 51 ( 3 ): 222 – 230.
dc.identifier.citedreferenceTaylor RJ, Miller JD, Rose AS, et al. Comprehensive quality of life outcomes for pediatric patients undergoing endoscopic sinus surgery. Rhinology. 2014; 52 ( 4 ): 327 – 333.
dc.identifier.citedreferenceAbuzeid WM, Song C, Fastenberg JH, et al. Correlations between cystic fibrosis genotype and sinus disease severity in chronic rhinosinusitis. Laryngoscope. 2018; 128 ( 8 ): 1752 – 1758.
dc.identifier.citedreferenceAyoub N, Thamboo A, Habib AR, Nayak JV, Hwang PH. Determinants and outcomes of upfront surgery versus medical therapy for chronic rhinosinusitis in cystic fibrosis. Int Forum Allergy Rhinol. 2017; 7 ( 5 ): 450 – 458.
dc.identifier.citedreferenceKanjanaumporn J, Hwang PH. Effect of endoscopic sinus surgery on bronchiectasis patients with chronic rhinosinusitis. Am J Rhinol Allergy. 2018; 32 ( 5 ): 432 – 439.
dc.identifier.citedreferenceKeck T, Rozsasi A. Medium‐term symptom outcomes after paranasal sinus surgery in children and young adults with cystic fibrosis. Laryngoscope. 2007; 117 ( 3 ): 475 – 479.
dc.identifier.citedreferenceTrust CF. Standards of Care and Good Clinical Practice for the Physiotherapy Management of Cystic Fibrosis. Trust CF; 2020.
dc.identifier.citedreferenceMogayzel PJ Jr, Naureckas ET, Robinson KA, et al. Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health. Am J Respir Crit Care Med. 2013; 187 ( 7 ): 680 – 689.
dc.identifier.citedreferenceFlume PA, Mogayzel PJ Jr, Robinson KA, et al. Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. Am J Respir Crit Care Med. 2009; 180 ( 9 ): 802 – 808.
dc.identifier.citedreferenceFlume PA, Robinson KA, O’Sullivan BP, et al. Cystic fibrosis pulmonary guidelines: airway clearance therapies. Respir Care. 2009; 54 ( 4 ): 522 – 537.
dc.identifier.citedreferenceCrifo S, Antonelli M, Gagliardi M, Lucarelli N, Marcolini P. Ototoxicity of aminoglucoside antibiotics in long‐term treatment for cystic fibrosis. Int J Pediatr Otorhinolaryngol. 1980; 2 ( 3 ): 251 – 253.
dc.identifier.citedreferencePiltcher OB, Teixeira VN, de Oliveira MW, Scattolin I, Piltcher SL. The prevalence of neurosensorial hearing loss among cystic fibrosis patients from Hospital de Clinicas de Porto Alegre. Int J Pediatr Otorhinolaryngol. 2003; 67 ( 9 ): 939 – 941.
dc.identifier.citedreferenceCheng AG, Johnston PR, Luz J, et al. Sensorineural hearing loss in patients with cystic fibrosis. Otolaryngol Head Neck Surg. 2009; 141 ( 1 ): 86 – 90.
dc.identifier.citedreferenceGleser MA, Zettner EM. Negative hearing effects of a single course of IV aminoglycoside therapy in cystic fibrosis patients. Int J Audiol. 2018; 57 ( 12 ): 917 – 924.
dc.identifier.citedreferenceTarshish Y, Huang L, Jackson FI, et al. Risk factors for hearing loss in patients with cystic fibrosis. J Am Acad Audiol. 2016; 27 ( 1 ): 6 – 12.
dc.identifier.citedreferenceAl‐Malky G, Suri R, Dawson SJ, Sirimanna T, Kemp D. Aminoglycoside antibiotics cochleotoxicity in paediatric cystic fibrosis (CF) patients: a study using extended high‐frequency audiometry and distortion product otoacoustic emissions. Int J Audiol. 2011; 50 ( 2 ): 112 – 122.
dc.identifier.citedreferenceHuth ME, Ricci AJ, Cheng AG. Mechanisms of aminoglycoside ototoxicity and targets of hair cell protection. Int J Otolaryngol. 2011; 2011: 937861.
dc.identifier.citedreferencevan Koningsbruggen‐Rietschel S, Heuer HE, Merkel N, et al. Pharmacokinetics and safety of an 8 week continuous treatment with once‐daily versus twice‐daily inhalation of tobramycin in cystic fibrosis patients. J Antimicrob Chemother. 2016; 71 ( 3 ): 711 – 717.
dc.identifier.citedreferencevan Velzen AJ, Uges JWF, Heijerman HGM, et al. Pharmacokinetics and safety of tobramycin nebulization with the I‐neb and PARI‐LC Plus in children with cystic fibrosis: a randomized, crossover study. Br J Clin Pharmacol. 2019; 85 ( 9 ): 1984 – 1993.
dc.identifier.citedreferenceGarinis AC, Poling GL, Rubenstein RC, et al. Clinical considerations for routine auditory and vestibular monitoring in patients with cystic fibrosis. Am J Audiol. 2021; 30 ( 3S ): 800 – 809.
dc.identifier.citedreferenceLourenco BM, Costa KM, da Silva Filho M. Voice disorder in cystic fibrosis patients. PLoS One. 2014; 9 ( 5 ): e96769.
dc.identifier.citedreferenceWillis J, Michael DD, Boyer H, Misono S. Prevalence and severity of dysphonia in patients with cystic fibrosis: a Pilot Study. Otolaryngol Head Neck Surg. 2015; 153 ( 1 ): 88 – 93.
dc.identifier.citedreferenceWilson JA, Deary IJ, Millar A, Mackenzie K. The quality of life impact of dysphonia. Clin Otolaryngol Allied Sci. 2002; 27 ( 3 ): 179 – 182.
dc.identifier.citedreferenceMacKenzie K, Millar A, Wilson JA, Sellars C, Deary IJ. Is voice therapy an effective treatment for dysphonia? A randomised controlled trial. BMJ. 2001; 323 ( 7314 ): 658 – 661.
dc.identifier.citedreferenceFlume PA, O’Sullivan BP, Robinson KA, et al. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med. 2007; 176 ( 10 ): 957 – 969.
dc.identifier.citedreferenceStevens DA, Moss RB, Kurup VP, et al. Allergic bronchopulmonary aspergillosis in cystic fibrosis–state of the art: Cystic Fibrosis Foundation Consensus Conference. Clin Infect Dis. 2003; 37 Suppl 3: S225 – S364.
dc.identifier.citedreferenceKaplan A. Canadian guidelines for chronic rhinosinusitis: clinical summary. Can Fam Physician. 2013; 59 ( 12 ):1275–1281, e528–e534.
dc.identifier.citedreferenceAlanin MC, Aanaes K, Hoiby N, et al. Sinus surgery postpones chronic Gram‐negative lung infection: cohort study of 106 patients with cystic fibrosis. Rhinology. 2016; 54 ( 3 ): 206 – 213.
dc.identifier.citedreferenceKhalfoun S, Tumin D, Ghossein M, Lind M, Hayes D. Improved lung function after sinus surgery in cystic fibrosis patients with moderate obstruction. Otolaryngol Head Neck Surg. 2018; 158 ( 2 ): 381 – 385.
dc.identifier.citedreferenceOsborn AJ, Leung R, Ratjen F, James AL. Effect of endoscopic sinus surgery on pulmonary function and microbial pathogens in a pediatric population with cystic fibrosis. Arch Otolaryngol Head Neck Surg. 2011; 137 ( 6 ): 542 – 547.
dc.identifier.citedreferenceBrietzke SE, Shin JJ, Choi S, et al. Clinical consensus statement: pediatric chronic rhinosinusitis. Otolaryngol Head Neck Surg. 2014; 151 ( 4 ): 542 – 553.
dc.identifier.citedreferenceGerber ME, Kennedy AA. Adenoidectomy with balloon catheter sinuplasty: a randomized trial for pediatric rhinosinusitis. Laryngoscope. 2018; 128 ( 12 ): 2893 – 2897.
dc.working.doiNOen
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
alr22974_am.pdf
Size:
1.215MB
Format:
PDF
View/Open
Name:
alr22974.pdf
Size:
286.6KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.